|
1
|
Oliver SE, Gunnell D and Donovan JL:
Comparison of trends in prostate cancer mortality in England and
Wales and the USA. Lancet. 355:1788–1789. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang M, Latham DE, Delaney MA and
Chakravarti A: Survivin mediates resistance to antiandrogen therapy
in prostate cancer. Oncogene. 24:2474–2482. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Krajewska M, Krajewski S, Banares S, Huang
X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A,
Peehl D, et al: Elevated expression of inhibitor of apoptosis
proteins in prostate cancer. Clin Cancer Res. 9:4914–4925.
2003.PubMed/NCBI
|
|
4
|
Shariat SF, Lotan Y, Saboorian H, Khoddami
SM, Roehrborn CG, Slawin KM and Ashfaq R: Survivin expression is
associated with features of biologically aggressive prostate
carcinoma. Cancer. 100:751–757. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ito T, Shiraki K, Sugimoto K, Yamanaka T,
Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, et
al: Survivin promotes cell proliferation in human hepatocellular
carcinoma. Hepatology. 31:1080–1085. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sui L, Dong Y, Ohno M, Watanabe Y,
Sugimoto K and Tokuda M: Survivin expression and its correlation
with cell proliferation and prognosis in epithelial ovarian tumors.
Int J Oncol. 21:315–320. 2002.PubMed/NCBI
|
|
8
|
Zaffaroni N, Pennati M, Colella G, Perego
P, Supino R, Gatti L, Pilotti S, Zunino F and Daidone MG:
Expression of the anti-apoptotic gene survivin correlates with
taxol resistance in human ovarian cancer. Cell Mol Life Sci.
59:1406–1412. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu B, Mu Y, Cao C, Zeng F, Schneider S,
Tan J, Price J, Chen J, Freeman M and Hallahan DE: Survivin as a
therapeutic target for radiation sensitization in lung cancer.
Cancer Res. 64:2840–2845. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kennedy SM, O'Driscoll L, Purcell R,
Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M,
Linehan R and Clynes M: Prognostic importance of survivin in breast
cancer. Br J Cancer. 88:1077–1083. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kishi H, Igawa M, Kikuno N, Yoshino T,
Urakami S and Shiina H: Expression of the survivin gene in prostate
cancer: Correlation with clinicopathological characteristics,
proliferative activity and apoptosis. J Urol. 171:1855–1860. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang M, Mukherjee N, Bermudez RS, Latham
DE, Delaney MA, Zietman AL, Shipley WU and Chakravarti A:
Adenovirus-mediated inhibition of survivin expression sensitizes
human prostate cancer cells to paclitaxel in vitro and in vivo.
Prostate. 64:293–302. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hayashi N, Asano K, Suzuki H, Yamamoto T,
Tanigawa N, Egawa S and Manome Y: Adenoviral infection of survivin
antisense sensitizes prostate cancer cells to etoposide in vivo.
Prostate. 65:10–19. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu
H, Liu MF and Wang ED: MicroRNA-155 functions as an OncomiR in
breast cancer by targeting the suppressor of cytokine signaling 1
gene. Cancer Res. 70:3119–3127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu C, Kelnar K, Liu B, Chen X,
Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et
al: The microRNA miR-34a inhibits prostate cancer stem cells and
metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Romano G, Acunzo M, Garofalo M, Di Leva G,
Cascione L, Zanca C, Bolon B, Condorelli G and Croce CM: MiR-494 is
regulated by ERK1/2 and modulates TRAIL-induced apoptosis in
non-small-cell lung cancer through BIM down-regulation. Proc Natl
Acad Sci USA. 109:16570–16575. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim WK, Park M, Kim YK, Tae YK, Yang HK,
Lee JM and Kim H: MicroRNA-494 downregulates KIT and inhibits
gastrointestinal stromal tumor cell proliferation. Clin Cancer Res.
17:7584–7594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Diakos C, Zhong S, Xiao Y, Zhou M,
Vasconcelos GM, Krapf G, Yeh RF, Zheng S, Kang M and Wiencke JK:
TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and
miRNA-320a. Blood. 116:4885–4893. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang SS, Jiang WW, Smith I, Poeta LM,
Begum S, Glazer C, Shan S, Westra W, Sidransky D and Califano JA:
MicroRNA alterations in head and neck squamous cell carcinoma. Int
J Cancer. 123:2791–2797. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe
TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, et al:
Genomic profiling of microRNA and messenger RNA reveals deregulated
microRNA expression in prostate cancer. Cancer Res. 68:6162–6170.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cao C, Mu Y, Hallahan DE and Lu B: XIAP
and survivin as therapeutic targets for radiation sensitization in
preclinical models of lung cancer. Oncogene. 23:7047–7052. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chakravarti A, Zhai GG, Zhang M, Malhotra
R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q and Loeffler J:
Survivin enhances radiation resistance in primary human
glioblastoma cells via caspase-independent mechanisms. Oncogene.
23:7494–7506. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Olie RA, Simões-Wüst AP, Baumann B, Leech
SH, Fabbro D, Stahel RA and Zangemeister-Wittke U: A novel
antisense oligonucleotide targeting survivin expression induces
apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer
Res. 60:2805–2809. 2000.PubMed/NCBI
|
|
24
|
Kato J, Kuwabara Y, Mitani M, Shinoda N,
Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J and
Fujii Y: Expression of survivin in esophageal cancer: Correlation
with the prognosis and response to chemotherapy. Int J Cancer.
95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Als AB, Dyrskjøt L, von der Maase H, Koed
K, Mansilla F, Toldbod HE, Jensen JL, Ulhøi BP, Sengeløv L, Jensen
KM and Orntoft TF: Emmprin and survivin predict response and
survival following cisplatin-containing chemotherapy in patients
with advanced bladder cancer. Clin Cancer Res. 13:4407–4414. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tolcher AW, Quinn DI, Ferrari A, Ahmann F,
Giaccone G, Drake T, Keating A and de Bono JS: A phase II study of
YM155, a novel small-molecule suppressor of survivin, in
castration-resistant taxane-pretreated prostate cancer. Ann Oncol.
23:968–973. 2012. View Article : Google Scholar
|
|
27
|
Wiechno P, Somer BG, Mellado B, Chłosta
PL, Cervera Grau JM, Castellano D, Reuter C, Stöckle M, Kamradt J,
Pikiel J, et al: A randomised phase 2 study combining LY2181308
sodium (survivin antisense oligonucleotide) with first-line
docetaxel/prednisone in patients with castration-resistant prostate
cancer. Eur Urol. 65:516–520. 2014. View Article : Google Scholar
|
|
28
|
Altieri DC: Validating survivin as a
cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ning S, Fuessel S, Kotzsch M, Kraemer K,
Kappler M, Schmidt U, Taubert H, Wirth MP and Meye A:
siRNA-mediated down-regulation of survivin inhibits bladder cancer
cell growth. Int J Oncol. 25:1065–1071. 2004.PubMed/NCBI
|
|
30
|
Sapra P, Wang M, Bandaru R, Zhao H,
Greenberger LM and Horak ID: Down-modulation of survivin expression
and inhibition of tumor growth in vivo by EZN-3042, a locked
nucleic acid antisense oligonucleotide. Nucleosides Nucleotides
Nucleic Acids. 29:97–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wiechno P, Chlosta P, Smok-Kalwat J,
Pikilel J, Henry D, Christianson D, Somer B, Mellado B, Duran I and
Castellano D: Interim results of a randomized phase II study with
window-design to evaluate antitumor activity of the survivin
antisense oligonucleotide (ASO) LY2181308 in combination with
docetaxel for first-line treatment of castrate-resistant prostate
cancer (CRPC). J Clin Oncol. 29(suppl): abstr 4592. 2011.
|
|
32
|
Song J, Cao L and Li Y: RNA
interference-mediated inhibition of survivin and VEGF in pancreatic
cancer cells in vitro. Mol Med Rep. 7:1651–1655. 2013.PubMed/NCBI
|
|
33
|
Liu Q, Fu H, Xing R, Tie Y, Zhu J, Sun Z
and Zheng X: Survivin knockdown combined with apoptin
overexpression inhibits cell growth significantly. Cancer Biol
Ther. 7:1053–1060. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shao Y, Liu Y, Shao C, Hu J, Li X, Li F,
Zhang L, Zhao D, Sun L, Zhao X, et al: Enhanced tumor suppression
in vitro and in vivo by co-expression of survivin-specific siRNA
and wild-type p53 protein. Cancer Gene Ther. 17:844–854. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baron M, Aslam H, Flasza M, Fostier M,
Higgs JE, Mazaleyrat SL and Wilkin MB: Multiple levels of Notch
signal regulation. Mol Membr Biol. 19:27–38. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang YS, Dai Y, Yu XF, Bao SY, Yin YB,
Tang M and Hu CX: Microarray analysis of microRNA expression in
hepatocellular carcinoma and non-tumorous tissues without viral
hepatitis. J Gastroenterol Hepatol. 23:87–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shen PF, Chen XQ, Liao YC, Chen N, Zhou Q,
Wei Q, Li X, Wang J and Zeng H: MicroRNA-494-3p targets CXCR4 to
suppress the proliferation, invasion and migration of prostate
cancer. Prostate. 74:756–767. 2014. View Article : Google Scholar : PubMed/NCBI
|
